Research on how cancer spreads through the body. Covers metastasis monitoring, bone metastasis, and nanoparticle treatments.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
Researchers at NUS have found that controlling TIP60 protein levels could prevent breast cancer cell spread. TIP60 interacts with DNMT1 and SNAIL2 to inhibit metastasis, suggesting a potential new strategy for treating various cancers.
Researchers at the University of Texas MD Anderson Cancer Center have discovered a link between the Golgi apparatus and lung cancer metastasis. The study found that targeting certain proteins in the Golgi can prevent tumor cells from spreading, offering a new potential therapeutic approach for preventing metastasis.
A new index called Lung-moIGPA has been developed to estimate survival in patients with non-small cell lung cancer and brain metastases. The updated Lung-moIGPA incorporates genetic and molecular data, including EGFR and ALK gene mutations, and predicts an overall median survival of 12 months.
A new study has identified BRD4 protein as a crucial driver of breast cancer cell dissemination, offering a promising new target for therapy. The findings may provide hope for patients with triple-negative breast cancer, the most aggressive and difficult-to-treat subtype.
Lung cancer is expected to result in an estimated 158,080 deaths in 2016 due to limited treatment options. Researchers are exploring signals within lung cancer cells that cause them to grow quickly and spread to other organs like the liver.
Researchers at Georgetown University Medical Center have developed a method to study cancer cell invasion and metastasis in real-time using zebrafish embryos. This approach allows for faster analysis of cancer questions, potentially leading to new treatments.
A team of scientists at the University of Alberta has discovered a protein marker, PDGFRA, that can help diagnose and treat aggressive papillary thyroid cancer. This finding could lead to more targeted treatments and reduce the need for unnecessary surgeries.
Researchers discovered that neutrophils, common white blood cells, can be hijacked by cancer cells to promote metastasis. A potential treatment using DNAse, an enzyme that degrades NETs, has shown promise in mice models of triple-negative breast cancer.
Researchers at the Research Institute of McGill University Health Centre (RI-MUHC) have discovered that some cancer cells can draw blood from existing mature blood vessels, allowing them to continue spreading. This breakthrough could lead to more personalized treatment options and improve the lives of patients with colon cancer.
PharmaMar's Phase 2 study shows significant reduction in tumor size and improved survival rates for patients with BRCA 1/2 metastatic breast cancer. The trial achieved an overall response rate of 41% with a 61% response rate in the BRCA 2 subgroup.
Tumor cells attract macrophages by releasing cytokines, which secrete growth factors that help tumor cells form spheroids and grow. Inhibiting these growth factors reduces tumor cell proliferation in a mouse model of ovarian cancer. This study sheds light on the early stages of ovarian tumor metastasis.
Cabozantinib significantly improves progression-free survival and response rate in patients with intermediate or poor-risk clear-cell metastatic renal cell carcinoma compared to sunitinib. The study also found a higher objective response rate in the cabozantinib arm.
Two phase II trials, KEYNOTE-052 and CheckMate 275, demonstrate the efficacy of PD-1 blockade with pembrolizumab and nivolumab in treating metastatic bladder cancer. The trials show a median survival benefit for patients with high PD-L1 expression.
Scientists from TUM discovered that pancreatic cancer cells create a 'niche' in the liver to grow and spread at an exceptionally early stage. This is facilitated by the protein TIMP1, which interacts with hepatic stellate cells to activate them and initiate metastasis.
Researchers harness microRNA therapy to block movement of cancer cells from primary tumors, preventing fatal proliferation and metastasis. The study's results suggest a promising approach for human breast cancer treatment.
Researchers at Sylvester Comprehensive Cancer Center have identified a receptor that slows breast cancer metastasis when targeted. By blocking the receptor for advanced glycation end-products (RAGE), scientists decreased tumor growth, reduced angiogenesis and inflammation, resulting in lower metastatic rates to the lung and liver.
Researchers found that pharmacological and genetic RANK pathway inhibition significantly reduced recurrences and metastases in a mouse animal model of breast cancer. This suggests RANK inhibitors used in osteoporosis treatment may also be effective against breast cancer.
Researchers have identified the ATG5 protein as a key regulator of metastatic capacity in melanomas. The study found that patients with partial loss of the ATG5 gene have a worse prognosis, developing metastasis and resistance to drugs.
Researchers found that whole brain radiotherapy had no beneficial effect on survival or quality of life compared to best supportive care and steroids. The trial included 538 patients with non-small cell lung cancer who had spread to the brain, and showed that WBRT did not extend survival or improve quality of life.
A new orthotopic animal model has been created to study metastasis in Ewing sarcoma, allowing researchers to replicate the primary tumor's growth environment. The model provides valuable insights into metastatic processes and may become a tool for analyzing metastatic potential in other sarcomas.
A new epigenetic test can diagnose the primary tumor responsible for metastasis in patients with Cancer of Unknown Primary (CUP), allowing for more specific treatments. This test, EPICUP, analyzes a patient's DNA to identify the type of cancer, resulting in improved survival rates.
Researchers discovered how lung's immune environment enables cancer to spread to the organ. Blocking oxygen-sensing proteins may enhance T-cell responses against cancer and limit metastasis.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
Researchers at UCF have discovered a way to kill spreading breast cancer cells using the peptide CT20. The therapy, called SEVA-108, targets metastatic cancer cells and has the potential to reduce traumatic side effects of traditional chemotherapies.
A Boston research team found that CT attenuation measurements can be used to differentiate between untreated osteoblastic (bone-related) metastases and enostoses (benign bone lesions). This discovery may help avoid unnecessary biopsies and radiologic studies.
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
A new study has identified a high prevalence of estrogen receptor mutations in patients with metastatic breast cancer, which are linked to poorer outcomes. The research found that 29 percent of patients had a mutation in the estrogen receptor, leading to reduced overall survival rates.
Cancer cells use DR6 to kill endothelial cells, allowing them to slip through the vascular wall and form metastases. This process is known as necroptosis, which enables cancer cells to overcome an endothelial cell layer in the laboratory and in living organisms.
PharmaMar starts a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or VCR for patients with SCLC after prior platinum-containing line failure. The primary endpoint is to improve progression-free survival.
Researchers at UCI have discovered a new treatment method for metastatic melanoma by blocking the 'don't eat me' signaling protein CD47 on melanoma cells, increasing their phagocytosis by macrophages. This approach, combined with targeting another cell surface protein CD271, resulted in near complete elimination of metastasis from mice.
A study at The University of Texas MD Anderson Cancer Center reveals protein ZMYND8's ability to block metastasis-linked gene expression in prostate cancer. ZMYND8 cooperates with histone mark eraser JARID1D to suppress metastasis-linked genes.
A review article aims to broaden radiologists' understanding of imaging-evident toxicity in the era of precision oncology. Toxicity can amplify with drug combinations, but acceptable levels may serve as a biomarker of treatment response. Radiologists must grasp the nuances of toxicity to contribute to optimized cancer care.
A study comparing SRS alone to SRS combined with WBRT found that SRS alone resulted in less cognitive deterioration at 3 months, with higher quality of life. The findings suggest that SRS alone may be a preferred strategy for patients with 1-3 brain metastases.
A new study pinpoints when melanoma cells metastasize to the brain months before they develop into fatal tumors. Researchers discovered that micro-tumor cells hijack astrogliosis to support metastatic growth, leading to potential early detection and intervention.
A significant increase in metastatic prostate cancer cases has been observed, particularly among men aged 55-69. This rise is attributed to changes in screening practices and highlights the need for refining prostate cancer screening and treatment in the US.
A recent study by Northwestern University found that metastatic prostate cancer cases have increased by 72% between 2004 and 2013, with men aged 55-69 being disproportionately affected. The study suggests that both more aggressive disease and lax screening may be contributing factors.
Researchers at Hokkaido University found that biglycan molecule attracts tumor cells to blood vessel walls, facilitating metastasis formation. High biglycan expression linked to poor prognosis in breast, lung, and colorectal cancer patients.
Researchers at Moffitt Cancer Center will investigate prostate cancer metastasis using a multi-disciplinary approach that integrates molecular, cellular and clinical information into mathematical models. The goal is to better understand the key factors driving disease progression and identify new therapeutic targets for prevention.
Researchers at Cold Spring Harbor Laboratory have identified a new pathway in ovarian cancer cells that can be targeted by drugs, reducing metastasis. The newly uncovered pathway depends on activity of protein FER, which activates receptor MET, leading to elevated motility and invasiveness.
The ESMO consensus guidelines reflect a personalized treatment approach to managing metastatic colorectal cancer, incorporating molecular markers and patient selection. The guidelines aim to improve outcomes by providing evidence-based recommendations for treatment options.
Scientists studied how cancer cells divide in capillaries using transparent nanofilms. Cell structures changed significantly, with membrane blebbing helping keep genetic material stable for healthy cell division.
A recent study by Queen Mary University of London has uncovered a previously unknown survival mechanism used by cancer cells to spread throughout the body. The researchers discovered that an integrin protein pairs with c-Met and signals within the cell to resist death, paving the way for new therapies to prevent metastasis.
Researchers developed an innovative nanoplatform to deliver RNAi agents to tumor sites, suppressing growth and reducing metastasis in preclinical models of anaplastic thyroid cancer. The platform, called theranostic, brings therapy and diagnosis together in one functional nanoparticle.
Research from Baylor College of Medicine found that Notch activation promotes metastasis in prostate cancer by upregulating FoxC2, a molecule important for metastatic potential. The study used a mouse model with prostate-specific loss-of-function Pten to demonstrate the role of Notch in prostate cancer progression.
A study published in JAMA Oncology shows that intrinsic molecular subtyping of breast cancer can predict patient outcomes and guide treatment decisions. The research found that the genomic classification of tumors is a key prognostic factor, outperforming traditional variables such as age and number of metastases.
Scientists have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells. The study shows how the metabolic signposts of cancer cell growth can be predicted based on EGFR signaling genes.
A new study led by MD Anderson Cancer Center found an eight-month progression-free survival benefit in patients treated with local consolidative therapy, a significant shift in clinical care for thousands of lung cancer patients. The treatment improved outcomes for those with oligometastases, defined as three or fewer sites of metastasis.
A small clinical trial found that combining checkpoint inhibitors with T-cell therapy may boost treatment effectiveness for metastatic melanoma. Researchers at Fred Hutchinson Cancer Center suggest this approach could be beneficial for fighting other cancers as well.
A Phase II clinical trial conducted by MD Anderson Cancer Center found that nivolumab significantly improves outcomes for patients with squamous cell carcinoma of the anal canal, with a control rate of 70%. The study enrolled 39 patients and demonstrated efficacy in both HIV-positive and non-HIV positive populations.
A crowd-sourcing strategy leveraging social media and advocacy groups has connected over 2,000 patients from all 50 states with the Metastatic Breast Cancer Project. This approach empowers patients to directly participate in research, improving outcomes for advanced breast cancer patients.
New research suggests that fluctuations in tRNA levels can have a dramatic impact on cellular function, driving metastatic breast cancer. The study found that two specific tRNAs were associated with increased metastasis, leading to changes in gene expression and protein production.
Researchers successfully treated a patient with metastatic melanoma using a combined approach of immunotherapy, including IL-21-primed polyclonal CTL plus CTLA4 blockade. The treatment led to the complete disappearance of tumors and sustained disease-free status for five years.
The IASLC consensus statement provides key pathologic, diagnostic, and therapeutic considerations for managing EGFR mutation positive NSCLC patients. It recommends optimal choice of EGFR TKIs, management of brain metastasis, and use of circulating free DNA for molecular studies.
Cancer cells use notch signaling pathways, particularly jagged, to communicate and coordinate their decisions to become motile and form clusters. This discovery offers a new target for disrupting metastasis and potentially diagnosing tumor severity.
A study by Jeremy Sanford's lab at UC Santa Cruz identified an extensive malignancy-associated gene expression circuit regulated by IGF2BP3 in pancreatic cancer cells. The protein drives metastasis by influencing the expression of genes involved in cancer biology, including cell migration and proliferation.
Researchers have identified a promising approach to treating triple-negative breast cancer (TNBC) by targeting the MYC oncogene. The study found that selective killing of MYC-overexpressing TNBC cells can be achieved through inhibition of cell cycle progression and fatty acid oxidation.
Researchers at the University of Chicago found that inhibiting autophagy, a cellular housekeeping process, effectively blocks tumor cell migration and breast cancer metastasis in tumor models. Autophagy is essential for tumor metastasis, and its inhibition can be an effective approach to block metastatic dissemination.
The Medical University of South Carolina's Hollings Cancer Center is awarded a grant to explore lipid signaling mechanisms in cancer cell proliferation, resistance to apoptosis, and metastasis. The project aims to develop new therapeutic strategies for solid tumors, including liver, prostate, and urinary cancers.
Researchers found that breast cancer cells spread by sliding around other cells blocking their escape route out of the original tumor. The study identified molecular pathways that regulate cell-sliding behavior and showed that increased levels of E-cadherin can diminish this behavior.